Copyright Reports & Markets. All rights reserved.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Growth (Status and Outlook) 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Report (Status and Outlook)

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2014-2024
        • 2.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Region
      • 2.2 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Type
        • 2.2.1 Drugs
        • 2.2.2 Invasive Procedures
        • 2.2.3 Device
      • 2.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
        • 2.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2014-2019)
        • 2.3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type (2014-2019)
      • 2.4 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Application
        • 2.4.1 Hospitals
        • 2.4.2 Clinics
        • 2.4.3 Other
      • 2.5 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
        • 2.5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2014-2019)
        • 2.5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Application (2014-2019)

      3 Global Benign Prostatic Hyperplasia (BPH) Treatment by Players

      • 3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Players
        • 3.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Players (2017-2019)
        • 3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Players (2017-2019)
      • 3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Products Offered
      • 3.3 Market Concentration Rate Analysis
        • 3.3.1 Competition Landscape Analysis
        • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.4 New Products and Potential Entrants
      • 3.5 Mergers & Acquisitions, Expansion

      4 Benign Prostatic Hyperplasia (BPH) Treatment by Regions

      • 4.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions
      • 4.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth
      • 4.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth
      • 4.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth
      • 4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth

      5 Americas

      • 5.1 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Countries
      • 5.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
      • 5.3 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Countries
      • 6.2 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
      • 6.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment by Countries
      • 7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
      • 7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment by Countries
      • 8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
      • 8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast

      • 10.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast (2019-2024)
      • 10.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Regions
        • 10.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Regions (2019-2024)
        • 10.2.2 Americas Market Forecast
        • 10.2.3 APAC Market Forecast
        • 10.2.4 Europe Market Forecast
        • 10.2.5 Middle East & Africa Market Forecast
      • 10.3 Americas Forecast by Countries
        • 10.3.1 United States Market Forecast
        • 10.3.2 Canada Market Forecast
        • 10.3.3 Mexico Market Forecast
        • 10.3.4 Brazil Market Forecast
      • 10.4 APAC Forecast by Countries
        • 10.4.1 China Market Forecast
        • 10.4.2 Japan Market Forecast
        • 10.4.3 Korea Market Forecast
        • 10.4.4 Southeast Asia Market Forecast
        • 10.4.5 India Market Forecast
        • 10.4.6 Australia Market Forecast
      • 10.5 Europe Forecast by Countries
        • 10.5.1 Germany Market Forecast
        • 10.5.2 France Market Forecast
        • 10.5.3 UK Market Forecast
        • 10.5.4 Italy Market Forecast
        • 10.5.5 Russia Market Forecast
        • 10.5.6 Spain Market Forecast
      • 10.6 Middle East & Africa Forecast by Countries
        • 10.6.1 Egypt Market Forecast
        • 10.6.2 South Africa Market Forecast
        • 10.6.3 Israel Market Forecast
        • 10.6.4 Turkey Market Forecast
        • 10.6.5 GCC Countries Market Forecast
      • 10.7 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Type
      • 10.8 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Application

      11 Key Players Analysis

      • 11.1 Astellas Pharma
        • 11.1.1 Company Details
        • 11.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.1.4 Main Business Overview
        • 11.1.5 Astellas Pharma News
      • 11.2 Eli Lilly
        • 11.2.1 Company Details
        • 11.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.2.4 Main Business Overview
        • 11.2.5 Eli Lilly News
      • 11.3 GlaxoSmithKline
        • 11.3.1 Company Details
        • 11.3.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.3.4 Main Business Overview
        • 11.3.5 GlaxoSmithKline News
      • 11.4 Sanofi
        • 11.4.1 Company Details
        • 11.4.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.4.4 Main Business Overview
        • 11.4.5 Sanofi News
      • 11.5 Novartis
        • 11.5.1 Company Details
        • 11.5.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.5.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.5.4 Main Business Overview
        • 11.5.5 Novartis News
      • 11.6 Teva
        • 11.6.1 Company Details
        • 11.6.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.6.3 Teva Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.6.4 Main Business Overview
        • 11.6.5 Teva News
      • 11.7 Boston Scientific
        • 11.7.1 Company Details
        • 11.7.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.7.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.7.4 Main Business Overview
        • 11.7.5 Boston Scientific News
      • 11.8 NxThera, Inc.(Rezum)
        • 11.8.1 Company Details
        • 11.8.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.8.3 NxThera, Inc.(Rezum) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.8.4 Main Business Overview
        • 11.8.5 NxThera, Inc.(Rezum) News
      • 11.9 NeoTract, Inc.(UroLift)
        • 11.9.1 Company Details
        • 11.9.2 Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
        • 11.9.3 NeoTract, Inc.(UroLift) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2019)
        • 11.9.4 Main Business Overview
        • 11.9.5 NeoTract, Inc.(UroLift) News

      12 Research Findings and Conclusion

      According to this study, over the next five years the Benign Prostatic Hyperplasia (BPH) Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Benign Prostatic Hyperplasia (BPH) Treatment business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares and growth opportunities of Benign Prostatic Hyperplasia (BPH) Treatment market by product type, application, key companies and key regions.

      This study considers the Benign Prostatic Hyperplasia (BPH) Treatment value generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
      Drugs
      Invasive Procedures
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
      Hospitals
      Clinics
      Other

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Astellas Pharma
      Eli Lilly
      GlaxoSmithKline
      Sanofi
      Novartis
      Teva
      Boston Scientific
      NxThera, Inc.(Rezum)
      NeoTract, Inc.(UroLift)

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Benign Prostatic Hyperplasia (BPH) Treatment market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Benign Prostatic Hyperplasia (BPH) Treatment market by identifying its various subsegments.
      Focuses on the key global Benign Prostatic Hyperplasia (BPH) Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Benign Prostatic Hyperplasia (BPH) Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the size of Benign Prostatic Hyperplasia (BPH) Treatment submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now